Public Equity Report: AnaptysBio, Avidity draw nine-digit offerings

With a premium-priced $100 million offering in hand, AnaptysBio Inc. (NASDAQ:ANAB) is eyeing a Phase III program for its BTLA agonist, as well as padding its balance sheet as it advances a new program into clinical testing.

The immunology-focused biotech said early Wednesday it had tapped a syndicate led by EcoR1 Capital for a registered direct offering that included strategic investor Sanofi (Euronext:SAN; NASDAQ:SNY) as well as Cormorant Asset Management, Farallon Capital Management, First Light Asset Management, Woodline Partners and other undisclosed firms...